Stay updated with breaking news from Nadege pelletier. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Barinthus Bio Announces Topline Data From Phase 1B/2 APOLLO Trial Of VTP-200 In Persistent High-Risk Human Papillomavirus (HPV) Infections menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
On Friday, Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, released topline final data from the APOLLO trial (. ....
Barinthus HPV-related cancer drug doesn't prove efficacy fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed. ....
Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events or serious AEs . Positive trends in clearance rate for both high-risk HPV. ....